Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, three tested clinico-pathological variables (extra thyroidal extension, intraglandular metastasis, and lymph node metastasis) were significant predictors of cyclin D1 immunostaining (P < 0.001).
|
30885146 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D1 and p21 expression levels were associated with regional lymph node metastases (both p<0.05) and Cyclin D1 expression levels significantly correlated with LSCC lymphatic invasion (x(2)=8.862; df=3; ?=0.031).
|
25536600 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Copy number and expression analysis of FOSL1, GSTP1, NTSR1, FADD and CCND1 genes in primary breast tumors with axillary lymph node metastasis.
|
27388253 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D1 overexpression was significantly associated with lymph node metastasis [OR 2.25; 95 % confidence interval (CI) 1.76-2.87] and worse disease-free survival (OR 3.06; 95 % CI 2.42-3.87].
|
25516222 |
2016 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
No difference in CCND1 gene expression between breast cancer patients with and without lymph node metastasis in a Southern Brazilian sample.
|
26409837 |
2016 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, amplification of CCND1 shows a negative predictive value of 80 % in the detection of LNM in early stage OSCCs which are clinically lymph node negative although this evidence is sparse and should be validated in a larger homogeneous cohort of T1-2 OSCC.
|
25663615 |
2015 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, amplification status of CCND1 and expression of CyclinD1 were evaluated by fluorescence in situ hybridization and immunohistochemistry on tissue microarrays from 152 lymph node-positive urothelial bladder cancers (one sample each from the center and invasion front of the primary tumors, two samples per corresponding lymph node metastasis) treated by cystectomy and lymphadenectomy.
|
23887292 |
2014 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The abnormal expression of β-catenin and the overexpression of cyclin D1 were correlated, and the overexpression of c-myc was correlated with tumor size, histological grade, clinical TNM stage and lymph node metastasis.
|
24190141 |
2014 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, no marked difference was noted in cyclin D1 expression between males and females, among patients in different age groups and between patients with and without lymph node metastasis (P>0.05).
|
23696923 |
2013 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These analyses also showed that a high TACSTD2 expression (P=0.003), a high Cyclin D1 expression (P=0.041), and lymph node metastasis (P=0.006) were independent prognosis factors.
|
23031786 |
2013 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among patients with muscle-invasive UCB, increased cyclin D1 expression in tumor cells significantly correlated with lymph node metastasis (p<0.001), and there was a trend of cyclin D1 together with lymph node positivity to be associated with disease recurrence (p=0.678).
|
24324055 |
2013 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCND1 amplification/overexpression was also significantly correlated with the lymph node metastasis of ESCC.
|
22761904 |
2012 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of key proteins in the MEK/ERK pathway, including p-p52Shc, Shc·Grb2 complexes, p-MEK, p-ERK, and cyclin D1, was significantly higher in patients with advanced FIGO stage, high grade, and lymph-node metastasis and correlated positively with serum insulin concentration.
|
22459351 |
2012 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, CCND1 is amplified and overexpressed in a substantial proportion of vulvar carcinomas and associated with the occurrence of locoregional lymph node metastases, especially in human papillomavirus-negative tumors.
|
22406359 |
2012 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymph node metastasis of cheek SCCs showed a trend towards a significant association (P= 0.098) with cyclin D1 amplification whereas the lymph node metastasis of tongue SCC was clearly not significant (P=0.593).There was a statistically significant correlation between cyclin D1 positivity and survival rate (P=0.009) for overall SCC cases and (P<0.001) for cheek SCC cases.
|
22296356 |
2011 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry for cyclin D1 and DNA flowcytometry for cell cycle parameters was done on paraffin embedded tumour samples from 45 patients with OSCC RESULTS: Higher expression of cyclin D1 was observed only in 30 (66.6%) of 45 cases that correlated with advanced age (P <0.02), higher tumour stage (P<0.01), histological differentiation and lymph node metastasis (P <0.01).
|
21537090 |
2011 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we determined clonal patterns by including CCND1 to compare the clonal constitution of primary tumors and associated lymph node metastases.
|
19893027 |
2009 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin D1 (P = 0.042) and CDK4 (P = 0.008) overexpession was inversely associated with lymph node metastasis and depth of invasion, respectively.
|
18484097 |
2008 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed the expression of S100A4, cyclin D1, p27 and MUC1, the presence of the BRAF V600E mutation and the clinicopathological features of the tumors, including patient age, tumor size (>or=5 vs <5 mm), extrathyroidal extension, multifocality, histological subtype, sclerosis and encapsulation, in a series of 198 papillary microcarcinomas in relation to lymph node metastasis to determine the predictive factors of lymph node metastasis.
|
18360353 |
2008 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study compared the Her-2, EGFR, and cyclin D1 status of primary tumors as well as their matching lymph node metastases using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) in 73 breast cancer patients.
|
19119452 |
2008 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin D1-positive phenotype was increased in primary carcinoma compared to non-neoplastic tissue, and was evident in all lymph node metastases cases.
|
17375037 |
2007 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also demonstrated that the AA genotype was associated with the occurrence of lymph node metastases (OR =3.26) and a higher level of cyclin D1 overexpression.
|
16258756 |
2006 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrations in CCND1 numbers appear to be valuable in identifying patients at high risk of late lymph node metastasis in Stage I and II OSCCs.
|
16265665 |
2005 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The CCND1 gene expression was associated with metastases to lymph nodes (p=0.0181) and also with distant metastasis (p=0.0204).
|
15993030 |
2005 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression rate of cyclin D1 protein in early stage gastric carcinoma, advanced gastric carcinoma and lymph node metastasis was 48.1%, 47.4% and 50.0%, respectively.
|
15378768 |
2004 |